Press

MINDCURE Announces Financial Results for Fiscal 2021

Sep 3 • 3 min read

VANCOUVER, BC, August 31, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research in psychedelics, today announced its financial results for the three and twelve months ended May 31, 2021. All amounts are stated in Canadian dollars unless otherwise indicated. …

Filament Health Files 20th Patent Application Including Three International Pct Applications

Sep 3 • 2 min read

Vancouver, British Columbia, September 1, 2021 – Filament Health Corp. NEO:FH. (“Filament” or the “Company”), a leading exclusively-natural psychedelic drug development company, today announced that it has filed its 20th patent application in support of the Company’s research phase programs. These filings include three international Patent Cooperation Treaty (PCT) patent applications. “This milestone sets us ahead of…

Field Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling Independent Psychedelic Therapists To Practice At Its Field Trip Health Centers

Sep 3 • 5 min read

Quick Take: The KAP Co-op program gives eligible therapists the ability to provide ketamine-assisted psychotherapy (KAP) to their patients at Field Trip Health Centers utilizing Field Trip’s medical teams for screening, prescribing and administration of ketamine. Field Trip Health Ltd. (Nasdaq: FTRP), a leader in the development and delivery of psychedelic therapies, is pleased to…

MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes

Sep 2 • 4 min read

Quick Take: MindMed and BioXcel have filed a patent that will help identify and prevent episodes of extreme agitated behavior in patients who may be more prone to agitation. MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. (“BioXcel”), a leading clinical-stage biopharmaceutical company, announce…

Ketamine One to Deploy Cognetivity’s Integrated Cognitive Assessment Tool

Sep 1 • 4 min read

Quick Take: Ketamine One has reached a commercial agreement with Cognetivity Neurosciences and will begin to use their Integrated Cognitive Assessment in their clinics. The ICA enables long-term monitoring of cognitive performance in patients with treatment-resistant depression and PTSD. KetamineOne Capital Limited (NEO: MEDI, OTC: KONEF), a company focused on consolidating medical clinics and becoming…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435